Agios

#AgiosNews: @EDE_UAE approved our first-in-class oral pyruvate kinase (PK) activator for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia – the only medicine approved in the UAE for this population. Read more: bit.ly/4d2buz0

Members of our Leadership Team will join a fireside chat at the TD Cowen Health Care Conference on March 2. The live webcast will be on the Investors section of our website, with a replay archived for at least 2 weeks. Listen and learn more: bit.ly/3OwPGBE

#AgiosNews: Today we reported our fourth quarter and full year 2025 financial results, along with recent business highlights. Read the press release and tune into the webcast this morning at 8:00 a.m. ET: bit.ly/4kwCdpp

We are hosting a conference call and live webcast on Thursday, February 12, at 8:00 a.m. ET to report and discuss our fourth quarter and full year 2025 financial results and other business highlights. Instructions on how to join the webcast are available here: bit.ly/4pZweKO

We’re on-site for #JPM26. Ahead of the meeting, we outlined our 2026 strategic priorities and key milestones across our #raredisease portfolio. Read our press release and tune in to our presentation on Wednesday, 1/14, at 8:15 a.m. PT to learn more: bit.ly/4qe0r9L

At #JPM26, we will share updates on our 2026 strategic priorities, our #raredisease pipeline, and the future outlook for the company. Learn more by tuning into our company presentation on Wednesday, January 14 at 8:15 a.m. PT / 11:15 a.m. ET: bit.ly/3Yp15VK

#AgiosNews: @US_FDA approved our first-in-class pyruvate kinase (PK) activator for the treatment of anemia in adults with alpha- or beta-thalassemia – regardless of transfusion status. Read more here: bit.ly/3Y7ofQv

#AgiosNews: Today we announced that the @US_FDA has not yet issued a decision on the sNDA for our first-in-class pyruvate kinase activator in adults with thalassemia and that the sNDA remains under active review. Read more here: bit.ly/4oE9xLi

We're at #ASH25 (booth #1661), connecting with the #hematology and #raredisease communities to explore the latest advances and share the progress of our pyruvate kinase (PK) activation franchise in rare blood disorders. Learn more about our presence at the meeting: bit.ly/48tp5vm

#AgiosNews: We announced topline results from the RISE UP Phase 3 trial of our first-in-class pyruvate kinase (PK) activator in patients aged 16+ with sickle cell disease. We intend to file for potential U.S. regulatory approval. Read about the results: bit.ly/47OiFbj

At #ASH25, we’re excited to showcase new data highlighting our first-in-class pyruvate kinase (PK) activator, share research led by two of our advisory councils, and strengthen our connections with the #hematology and #raredisease communities. Read more: bit.ly/439wwpS

#AgiosNews: Today, we reported our third quarter 2025 financial results, along with recent business highlights. Read the press release and tune into the webcast this morning at 8:00 a.m. ET: bit.ly/4hAhfEn

#AgiosNews: EMA’s CHMP adopted a positive opinion for our first-in-class PK activator for the treatment of anemia in adult patients with #thalassemia. Decision from European Commission is expected by early 2026. Read our press release: bit.ly/42MZtb3

We are hosting a conference call and live webcast on Thursday, October 30, at 8:00 a.m. ET to report and discuss our third quarter 2025 financial results and other business highlights. Instructions on how to join the webcast are available here: bit.ly/4qewS8A

We’re at #ASCAT2025, joining the #SickleCellDisease and #Thalassemia communities and our other partners to share scientific progress and advance support for people living with these rare diseases. Visit us at booth #14 – we’d love to connect.

#AgiosNews: The PDUFA goal date for the U.S. sNDA of our first-in-class PK activator for the treatment of adult patients with thalassemia has been extended by three months, from September 7, 2025, to December 7, 2025. Read our press release for more information: bit.ly/4mPQBJE

#AgiosNews: @Saudi_fda_en approved our first-in-class pyruvate kinase (PK) activator for the treatment of adult patients with thalassemia. This marks the first regulatory approval for this medicine in thalassemia. Read more: bit.ly/4mqLyP4